SCHEMBL122647

SCHEMBL122647

CCCCCO[C@@H]1C=C(C(=O)O)C[C@H](N)[C@H]1NC(C)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14950040 0.91
SCHEMBL4082947 0.89
SCHEMBL1255188 0.87 MEN1 (0.59)
SCHEMBL19288192 0.81
SCHEMBL23388213 0.80
SCHEMBL15380920 0.80
SCHEMBL4085280 0.79 MEN1 (0.62)
Oseltamivir Carboxylate SCHEMBL1977050 0.78
Oseltamivir Carboxylate SCHEMBL20607528 0.78
Oseltamivir Carboxylate SCHEMBL14080012 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021099419-A1 METHOD FOR PRODUCING REASSORTANT INFLUENZA VIRUSES Seqirus UK Limited (GB) 2021-05-27 WO disclosed
EP-3197487-A1 VACCINATION OF IMMUNOCOMPROMISED SUBJECTS Seqirus UK Limited (GB) 2017-08-02 EP disclosed
EP-3004332-A2 INFLUENZA VIRUS REASSORTMENT Novartis AG (CH) 2016-04-13 EP disclosed
WO-2016046799-A1 VACCINATION OF IMMUNOCOMPROMISED SUBJECTS Seqirus UK Limited (GB) 2016-03-31 WO disclosed
EP-2968512-A2 INFLUENZA B VIRUS REASSORTMENT Novartis AG (CH) 2016-01-20 EP disclosed
EP-2948175-A1 INFLUENZA VIRUS REASSORTMENT Novartis AG (CH) 2015-12-02 EP disclosed
EP-2925356-A2 REASSORTANT INFLUENZA A VIREN Novartis AG (CH) 2015-10-07 EP disclosed
US-20150246110-A1 ADJUVANTED INFLUENZA VACCINES INCLUDING CYTOKINE-INDUCING AGENTS NOVARTIS AG (CH) 2015-09-03 US disclosed
EP-2906231-A2 INFLUENZA VIRUS AND TYPE 1 DIABETES Ospedale San Raffaele S.r.l. (IT) 2015-08-19 EP disclosed
EP-2396030-B1 INFLUENZA VACCINE REGIMENS FOR PANDEMIC-ASSOCIATED STRAINS NOVARTIS AG (CH) 2015-08-12 EP disclosed
WO-2007085969-A2 INFLUENZA VACCINES CONTAINING HEMAGGLUTININ AND MATRIX PROTEINS NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG (DE) 2007-08-02 WO disclosed
WO-2007052056-A1 ADJUVANTED INFLUENZA VACCINES INCLUDING CYTOKINE-INDUCING AGENTS NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-05-10 WO disclosed
WO-2007052055-A1 ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-05-10 WO disclosed
WO-2007052163-A2 CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA BY BETA-PROPIOLACTONE TREATMENT NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG (DE) 2007-05-10 WO disclosed
WO-2007052060-A1 INFLUENZA VACCINES EXTEMPORANEOUSLY ADSORBED TO ALUMINIUM ADJUVANTS NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-05-10 WO disclosed
WO-2007052057-A2 ADMINSTRATION ROUTES FOR PRIMING/BOOSTING WITH INFLUENZA VACCINES NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-05-10 WO disclosed
WO-2007052155-A2 INFLUENZA VACCINE WITH REDUCED AMOUNT OF OIL-IN-WATER EMULSION AS ADJUVANT NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-05-10 WO disclosed
WO-2007052061-A2 EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT AS ADJUVANTS FOR SPLIT INFLUENZA VACCINES NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-05-10 WO disclosed
WO-2007052058-A1 INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-05-10 WO disclosed
WO-2007052059-A2 CHANGING TH1/TH2 BALANCE IN SPLIT INFLUENZA VACCINES WITH ADJUVANTS NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-05-10 WO disclosed